CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons von Tefferi, A, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R, Hanson, C H, Maffioli, M, Caramazza, D, Passamonti, F, Pardanani, A

Volltext

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms von Abdel-Wahab, O, Pardanani, A, Rampal, R, Lasho, T L, Levine, R L, Tefferi, A

Volltext

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia von Pardanani, A, Lasho, T L, Laborde, R R, Elliott, M, Hanson, C A, Knudson, R A, Ketterling, R P, Maxson, J E, Tyner, J W, Tefferi, A

Volltext

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients von Tefferi, A, Guglielmelli, P, Lasho, T L, Rotunno, G, Finke, C, Mannarelli, C, Belachew, A A, Pancrazzi, A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A, Vannucchi, A M

Volltext

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis von Tefferi, A, Pardanani, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Gangat, N, Finke, C M, Schwager, S, Mullally, A, Li, C-Y, Hanson, C A, Mesa, R, Bernard, O, Delhommeau, F, Vainchenker, W, Gilliland, D G, Levine, R L

Volltext

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact von Tefferi, A, Lasho, T L, Finke, C, Belachew, A A, Wassie, E A, Ketterling, R P, Hanson, C A, Pardanani, A

Volltext

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients von Patnaik, M M, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Tefferi, A, Solary, E

Volltext

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates von Tefferi, A, Levine, R L, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Finke, C M, Mullally, A, Li, C-Y, Pardanani, A, Gilliland, D G

Volltext

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms von Pardanani, A, Lasho, T L, Finke, C M, Mai, M, McClure, R F, Tefferi, A

Volltext

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis von Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A

Volltext

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F von Tefferi, A, Jimma, T, Sulai, N H, Lasho, T L, Finke, C M, Knudson, R A, McClure, R F, Pardanani, A

Volltext

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients von Guglielmelli, P, Lasho, T L, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, Biamonte, F, Pardanani, A, Zoi, K, Reiter, A, Duncombe, A, Fanelli, T, Pietra, D, Rumi, E, Finke, C, Gangat, N, Ketterling, R P, Knudson, R A, Hanson, C A, Bosi, A, Pereira, A, Manfredini, R, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Vannucchi, A M, Tefferi, A

Volltext

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML von Tefferi, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Patnaik, M M, Hanson, C A, Pardanani, A, Gilliland, D G, Levine, R L

Volltext

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis von Tefferi, A, Lasho, T L, Abdel-Wahab, O, Guglielmelli, P, Patel, J, Caramazza, D, Pieri, L, Finke, C M, Kilpivaara, O, Wadleigh, M, Mai, M, McClure, R F, Gilliland, D G, Levine, R L, Pardanani, A, Vannucchi, A M

Volltext

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients von Cerquozzi, S., Barraco, D., Lasho, T., Finke, C., Hanson, C. A., Ketterling, R. P., Pardanani, A., Gangat, N., Tefferi, A.

Volltext

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients von Lasho, T L, Finke, C M, Hanson, C A, Jimma, T, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms von Abdel-Wahab, O, Pardanani, A, Patel, J, Wadleigh, M, Lasho, T, Heguy, A, Beran, M, Gilliland, D G, Levine, R L, Tefferi, A

Volltext

Calreticulin mutations and long-term survival in essential thrombocythemia von Tefferi, A, Wassie, E A, Lasho, T L, Finke, C, Belachew, A A, Ketterling, R P, Hanson, C A, Pardanani, A, Gangat, N, Wolanskyj, A P

Volltext

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients von Patnaik, M M, Hanson, C A, Hodnefield, J M, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R P, Pardanani, A, Tefferi, A

Volltext

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis von Tefferi, A, Lasho, T L, Finke, C, Gangat, N, Hanson, C A, Ketterling, R P, Pardanani, A

Volltext